ABSTRACT
BACKGROUND
METHODS
RESULTS
CONCLUSIONS
Keywords
INTRODUCTION
METHODS
Study design
Study visits and data collection

Operative technique and administration of Lymfactin®
Study objectives
Volume measurements
Qualitative lymphoscintigraphy
Quality of Life
Statistical analysis
RESULTS
Participants
Safety profile
Lymphoscintigraphy

Volume measurements - with garment and 7 days after garment removal


Volume measurements and clinical symptoms of the donor limb

Quality of Life

DISCUSSION

CONFLICTS OF INTEREST
ACKNOWLEDGEMENTS
FUNDING
ETHICAL APPROVAL
Appendix. Supplementary materials
Word document, Supplemental digital content 1
Details of patient selection and post-treatment therapy.
Table, Supplemental digital content 2
Patients’ breast cancer and lymphedema histories are summarized in supplemental table.
REFERENCES
- Incidence of unilateral arm lymphoedema after breast cancer: A systematic review and meta-analysis.Lancet Oncol. 2013; 14: 500-515
- Risk of lymphedema following contemporary treatment for breast cancer: An analysis of 7617 consecutive patients from a multidisciplinary perspective.Ann Surg. 2019;
- Postmastectomy lymphedema: Long-term results following microsurgical lymph node transplantation.Ann Surg. 2006; 243: 313-315
- Microvascular breast reconstruction and lymph node transfer for postmastectomy lymphedema patients.Ann Surg. 2012; 255: 468-473
- Lymphatic vessel function and lymphatic growth factor secretion after microvascular lymph node transfer on lymphedema patients. Plastic and Reconstructive Surgery Global Open.PRS GO. 2013; 1: 1-9
- Free vascularized lymph node transfer for treatment of lymphedema: A systematic evidence based review.J Plast Reconstr Aesthet Surg. 2016; 69: 1234-1247
- Vascularized lymph node transfer for treatment of lymphedema: A comprehensive literature review.Ann Surg. 2015; 261: 1013-1023
- Growth factor therapy and autologous lymph node transfer in lymphedema.Circulation. 2011; 123: 613-620
- Lymph node transfer and perinodal lymphatic growth factor treatment for lymphedema.Ann Surg. 2012; 257: 961-967
- Novel combined surgical treatment for chronic lymphedema patients: Simultaneous lymph node transfer and liposuction, accepted for publication.Ann Plast Surg. 2019; 83: 308-317
- Insights into the molecular pathogenesis and targeted treatment of lymphedema.Ann N Y Acad Sci. 2002; 979: 94-110
- Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia.Circulation. 1998; 97: 1114-1123
- Lymphangiogenic gene therapy with minimal blood vascular side effects.J Exp Med. 2002; 196: 719-730
- Therapeutic differentiation and maturation of lymphatic vessels after lymph node dissection and transplantation.Nat Med. 2007; 13: 1458-1466
- VEGF-C and VEGF-C156S in the pro-lymphangiogenic growth factor therapy of lymphedema: A large animal study.Angiogenesis. 2015; 18: 313-326
- Growth factor therapy and lymph node graft for lymphedema.J Surg Res. 2015; 196: 200-207
- Targeted treatment for lymphedema and lymphatic metastasis.Ann N Y Acad Sci. 2008; 1131: 215-224
- Phase 1 LymfactinⓇ Study: Short-term Safety of Combined Adenoviral VEGF-C and Lymph Node Transfer Treatment for Upper Extremity Lymphedema.J Plast Reconstr Aesthet Surg. 2020; 73: 1612-1621
- Risk of donor-site lymphatic vessel dysfunction after microvascular lymph node transfer.J Plast Reconstr Aesthet Surg. 2015; 68: 551-558
- Donor-site lymphatic function after microvascular lymph node transfer.Plast Reconstr Surg. 2012; 130: 1246-1253
- Standardised measurements used to order compression garments can be used to calculate arm volumes to evaluate lymphoedema treatment.J Plast Surg Hand Surg. 2012; 46: 410-415
- Evaluation of transport kinetics in lymphoscintigraphy: follow-up study in patients with transplanted lymphatic vessels.Eur J Nucl Med. 1985; 10: 349-352
- Post-therapeutic lymphedema: Scintigraphy before and after autologous lymph vessel transplantation: 8 years of long-term follow-up.Clin Nucl Med. 2002; 27: 788-792
- Assessment of quality of life in lymphedema patients: validity andreliability of the Swedish version of the lymphedema quality of life inventory (LQOLI).Lymphology. 2010; 43: 135-145
- Outcomes for Physiologic Microsurgical Treatment of Secondary Lymphedema Involving the Extremity.Ann Surg. 2020;
- Liposuction combined with controlled compression therapy reduces arm lymphedema more effectively than controlled compression therapy alone.Plast Reconstr Surg. 1998; 102: 1058-1067
- The diagnosis and treatment of peripheral lymphedema. Consensus document of the International Society of Lymphology.Lymphology. 2003; 36: 84-91
- Liposuction reduces arm lymphedema without significantly altering the already impaired lymph transport.Lymphology. 1998; 31: 156-172
- Systematic Review of the Surgical Treatment of Extremity Lymphedema.J Reconstr Microsurg. 2017; 33: 412-425
- Systematic Review of Patient-Reported Outcomes following Surgical Treatment of Lymphedema.Cancers (Basel). 2020; 12: 565
- Comprehensive review of vascularized lymph node transfers for lymphedema: Outcomes and complications.Microsurgery. 2018; 38: 222-229
Article info
Publication history
Footnotes
The study identifier number at ClinicalTrials.gov is NCT02994771
Financial Disclosure Statement
PH, SS, ES, IK, TV, and AS have received honoraria for participating in advisory boards of Herantis Pharma Plc. (Espoo, Finland). KA has been a consultant for Herantis Pharma Plc. AV and OL are employees of Herantis Pharma Plc. (Espoo, Finland). This trial was supported by Herantis Pharma Plc. (Espoo, Finland). The sponsor has been responsible for trial management and has also reviewed this manuscript.
Identification
Copyright
User license
Creative Commons Attribution (CC BY 4.0) |
Permitted
- Read, print & download
- Redistribute or republish the final article
- Text & data mine
- Translate the article
- Reuse portions or extracts from the article in other works
- Sell or re-use for commercial purposes
Elsevier's open access license policy